Panamesine

Panamesine ( ; developmental code name EMD-57455) is a sigma receptor antagonist that was under development by Merck as a potential antipsychotic for the treatment of schizophrenia in the 1990s but was never marketed.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Panamesine ( ; developmental code name EMD-57455) is a sigma receptor antagonist that was under development by Merck as a potential antipsychotic for the treatment of schizophrenia in the 1990s but was never marketed. It is a selective antagonist of both sigma receptor subtypes, the σ 1 and σ 2 receptors (IC 50 = 6 nM).

In addition, the major metabolite of the drug, EMD-59983, has high affinity for the sigma receptors (IC 50 = 24 nM) and the dopamine D 2 (IC 50 = 23 nM) and D 3 receptors, with potent antidopaminergic activity. Panamesine reached phase II clinical trials for schizophrenia prior to the discontinuation of its development. CNS review:

Panamesine ( ; developmental code name EMD-57455) is a sigma receptor antagonist that was under development by Merck as a potential antipsychotic for the treatment of schizophrenia in the 1990s but was never marketed. It is a selective antagonist of both sigma receptor subtypes, the σ 1 and σ 2 receptors (IC 50 = 6 nM).

In addition, the major metabolite of the drug, EMD-59983, has high affinity for the sigma receptors (IC 50 = 24 nM) and the dopamine D 2 (IC 50 = 23 nM) and D 3 receptors, with potent antidopaminergic activity. Panamesine reached phase II clinical trials for schizophrenia prior to the discontinuation of its development. CNS review:

See also

List of investigational antipsychotics BMY-14802 Eliprodil Rimcazole

Text derived from https://en.wikipedia.org/w/index.php?oldid=1371987952 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.